These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 23852665)

  • 1. The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.
    Diéras V; Bachelot T
    Target Oncol; 2014 Jun; 9(2):111-22. PubMed ID: 23852665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.
    Kashiwaba M; Ito Y; Takao S; Doihara H; Rai Y; Kanatani K; Takashima S; Masuda N
    Jpn J Clin Oncol; 2016 May; 46(5):407-14. PubMed ID: 26917603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab emtansine for HER2-positive advanced breast cancer.
    Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
    N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
    Krop IE; Kim SB; González-Martín A; LoRusso PM; Ferrero JM; Smitt M; Yu R; Leung AC; Wildiers H;
    Lancet Oncol; 2014 Jun; 15(7):689-99. PubMed ID: 24793816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy.
    Dhillon S
    Drugs; 2014 Apr; 74(6):675-86. PubMed ID: 24659374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
    Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
    Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].
    Guerin M; Sabatier R; Gonçalves A
    Bull Cancer; 2015 Apr; 102(4):390-7. PubMed ID: 25790739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
    Krop IE; Lin NU; Blackwell K; Guardino E; Huober J; Lu M; Miles D; Samant M; Welslau M; Diéras V
    Ann Oncol; 2015 Jan; 26(1):113-119. PubMed ID: 25355722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I; Winer EP
    Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
    Van den Mooter T; Teuwen LA; Rutten A; Dirix L
    Expert Opin Biol Ther; 2015 May; 15(5):749-60. PubMed ID: 25865453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
    Haddley K
    Drugs Today (Barc); 2013 Nov; 49(11):701-15. PubMed ID: 24308017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.
    Yamamoto H; Ando M; Aogi K; Iwata H; Tamura K; Yonemori K; Shimizu C; Hara F; Takabatake D; Hattori M; Asakawa T; Fujiwara Y
    Jpn J Clin Oncol; 2015 Jan; 45(1):12-8. PubMed ID: 25332421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
    Barginear MF; John V; Budman DR
    Mol Med; 2013 Jan; 18(1):1473-9. PubMed ID: 23196784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.